Read by QxMD icon Read

Topical tacrolimus

Philippe A Eigenmann
Skin diseases related to allergy are common in childhood and pediatric allergists are commonly faced with atopic eczema, treatment schemes for which include calcineurin inhibitors: commonly used topical drugs which control inflammatory skin flares. In the first review of this issue, Nakahira et al provide mechanistic insights, among others, into modulation of the immune response by tacrolimus (1). Prevention of atopic eczema is addressed by Wickens et al. This article is protected by copyright. All rights reserved...
March 13, 2018: Pediatric Allergy and Immunology
JiaLi Xu, YaDong Feng, GuoXin Song, QiXing Gong, Li Yin, YingYing Hu, Dan Luo, ZhiQiang Yin
Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control , Tacrolimus (0...
2018: Frontiers in Pharmacology
Grace Thompson, Andrew Mclean-Tooke, Jeremy Wrobel, Melanie Lavender, Michaela Lucas
Interstitial lung disease (ILD) is a significant complication of Sjögren syndrome (SS) associated with increased morbidity and mortality. The mainstay of treatment remains corticosteroid administration, with or without additional immunosuppressive therapies. Preliminary studies in SS have shown benefit in glandular and serologic parameters following treatment with the CTLA4 immunoglobulin fusion protein abatacept. Topical tacrolimus has been effective for ocular symptoms in SS, but systemic therapy has not been reported...
March 2018: Chest
Georgios Kravvas, Karolina Gholam
Psoriasis is one of the most common chronic skin diseases, affecting 1%-3% of the general population. It can have a significant negative impact on a patient's quality of life, and in approximately 30% of patients first symptoms can be traced back to childhood. We have performed a comprehensive literature search using the MEDLINE database in order to ascertain the efficacy and adverse reactions of topical treatments in pediatric psoriasis. A total of 13 relevant articles were identified on the following topical agents: corticosteroids, calcineurin inhibitors, vitamin D analogs, and dithranol...
March 1, 2018: Pediatric Dermatology
Elvira León-Muiños, Olalla Figueroa, Laura Rosende, Benigno Monteagudo
No abstract text is available yet for this article.
February 12, 2018: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
Yu-Chi Liu, Xu Wen Ng, Ericia Pei Wen Teo, Heng-Pei Ang, Nyein Chan Lwin, Nicole Shu Wen Chan, Subbu S Venkatraman, Tina T Wong, Jodhbir S Mehta
Purpose: To investigate the drug release profiles of a tacrolimus-loaded poly(D,L-lactide-co-ε-caprolactone) (PLC) microfilm, and to evaluate its efficacy on the treatment of allergic conjunctivitis using a mouse model. Methods: The in vitro and in vivo drug release profiles were first characterized. Balb/c mice were immunized with short ragweed (SRW) injection followed by re-challenges with topical SRW solution. The mice were divided into six groups (n = 12 in each): negative control (NC); positive control (PC); tacrolimus eye drops (Te); subconjunctival tacrolimus microfilm (Tm); dexamethasone eye drops (De); and tacrolimus + dexamethasone eye drops (Te+De)...
February 1, 2018: Investigative Ophthalmology & Visual Science
Sébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, Pascal Juillerat, Andreas Nydegger, Alex Straumann, Stephan Vavricka, Luc Biedermann, Thomas Greuter, Montserrat Fraga, Karim Abdelrahman, Dieter Hahnloser, Bernhard Sauter, Gerhard Rogler, Pierre Michetti, Alain M Schoepfer
BACKGROUND AND AIM: Systematic analyses of inflammatory bowel disease (IBD) drug-related side effects necessitating treatment cessation in large cohorts of patients with IBD are scarce. We aimed to assess the frequency and type of drug-related side effects requiring drug cessation in patients included in the Swiss IBD Cohort. PATIENTS AND METHODS: A retrospective review was performed of data from the Swiss IBD Cohort physician questionnaires documenting a treatment cessation for the following drug categories: aminosalicylates, topical and systemic steroids, thiopurines, methotrexate, tumor necrosis factor-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine)...
January 30, 2018: European Journal of Gastroenterology & Hepatology
Claudio Marasca, Maria C Annunziata, Anna Masarà, Gabriella Fabbrocini
No abstract text is available yet for this article.
January 24, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
Maddalena Napolitano, Matteo Megna, Angela Patrì, Giuseppe Monfrecola, Nicola Balato
No abstract text is available yet for this article.
January 24, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
Lionel Sebbag, Patricia A Pesavento, Sebastian E Carrasco, Christopher M Reilly, David J Maggs
Case summary: A 14-year-old female spayed Abyssinian cat, which about 1 year previously underwent thoracic limb amputation, radiotherapy and chemotherapy for an incompletely excised vaccine-related fibrosarcoma, was presented for evaluation of corneal opacity in the left eye (OS). The ocular surface of both eyes (OU) had a lackluster appearance and there was a stromal corneal ulcer OS. Results of corneal aesthesiometry, Schirmer tear test-1 (STT-1) and tear film breakup time revealed corneal hypoesthesia, and quantitative and qualitative tear film deficiency OU...
January 2018: JFMS Open Reports
Kaiyue Yu, Yixuan Wang, Tao Wan, Yuanhao Zhai, Sisi Cao, Wenyi Ruan, Chuanbin Wu, Yuehong Xu
Background: Topical application of tacrolimus (FK506) was effective in the treatment of atopic dermatitis (AD); however, adverse effects frequently occurred with the increase of FK506 dose during long-term treatment. Objective: The objective of this project was to develop a hybrid skin targeting system encapsulating FK506 based on nicotinamide (NIC) and chitosan nanoparticles (CS-NPs), ie, FK506-NIC-CS-NPs, which took advantages of both of NIC and CS-NPs to obtain the synergetic effects of percutaneous delivery and treatment efficacy enhancement along with dose reduction...
2018: International Journal of Nanomedicine
Takanori Iwayama, Takeshi Fukumoto, Nobuyuki Horita, Masanobu Sakaguchi, Masahiro Oka, Hiroto Terashi
No abstract text is available yet for this article.
December 1, 2017: European Journal of Dermatology: EJD
Markus V Heppt, Valerie Letulé, Ieva Laniauskaite, Markus Reinholz, Julia K Tietze, Hans Wolff, Thomas Ruzicka, Elke C Sattler
Frontal fibrosing alopecia (FFA) describes the scarring, band-like recession of the frontotemporal hairline. Treatment is difficult, and currently, no evidence-based therapy exists. The purpose of this study is to report clinical features and treatment responses in a large cohort of patients with FFA. The authors analyzed a series of 72 patients with a clinical or histologic diagnosis of FFA. A total of 70 patients were female (97.2%), and 2 were male (2.8%). In females, the first onset of FFA was postmenopausal in 81...
December 26, 2017: Facial Plastic Surgery: FPS
Preethi S Ganapathy, Thomas Plesec, Arun D Singh
Purpose: To describe a case of diffuse conjunctival papilloma in an immunocompromised individual on tacrolimus that was refractory to treatment with interferon α-2b, but responded to topical mitomycin-c. Observations: A 79-year-old Caucasian female with a history of a liver transplant twenty years ago, who was immunosuppressed with tacrolimus (2 mg daily) presented with a diffuse conjunctival and corneal squamous papilloma. Following treatment with four weekly subconjunctival interferon-α2b injections (3 million units/0...
June 2017: American Journal of Ophthalmology Case Reports
B Aranegui, J Jiménez-Reyes
Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as localized juvenile scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0...
December 13, 2017: Actas Dermo-sifiliográficas
Apoorva Trivedi, Corey M DeWitt, Laura McGevna
Radiation-induced morphea (RIM) is a rare and underrecognized complication of radiation therapy that most commonly occurs in women after treatment for breast cancer. Although not fully understood, RIM is hypothesized to arise from an increase in cytokines that stimulate collagen production and extracellular matrix formation. Most documented cases of RIM occur 1 year after radiation therapy and are localized to areas that were treated for breast cancer. We report on a case of a female patient with stage IB endometrial adenocarcinoma who was treated with 24 Gray of adjuvant brachytherapy...
December 2017: International Journal of Women's Dermatology
Mohammad Nasser Hashemian, Golshan Latifi, Reza Ghaffari, Hamed Ghassemi, Mehran Zarei Ghanavati, Seyed-Farzad Mohammadi, Mehdi Yasseri, Mohammad Reza Fallah Tafti, Zahra Fallah Tafti
PURPOSE: To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft. METHODS: Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups-group 1: receiving topical tacrolimus 0.05% as adjuvant therapy to corticosteroid treatment and group 2: receiving only corticosteroid treatment. Main outcome measures were rejection reversal, time to rejection reversal, and recurrence of rejection...
March 2018: Cornea
Takeshi Nakahara, Hiroshi Morimoto, Naofumi Murakami, Masutaka Furue
More than 15 years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids...
December 4, 2017: Pediatric Allergy and Immunology
Ana Carolina F Motta, Qian Zhan, Allison Larson, Mark Lerman, Sook-Bin Woo, Robert J Soiffer, George F Murphy, Nathaniel S Treister
OBJECTIVE: To characterize the immunohistopathologic features of oral chronic graft-versus-host disease (cGVHD), and the impact of topical immunomodulatory therapy on the infiltrating cells. MATERIAL AND METHODS: Paired oral cGVHD biopsies obtained before (n=12) and one month after treatment (n=12) with topical dexamethasone (n=8) or tacrolimus (n=4) were characterized by immunohistochemistry using a panel of CD1a, CD3, CD4, CD8, CD20, CD31, CD62E, CD103, CD163, c-kit and FoxP3...
December 2, 2017: Oral Diseases
Stephanie R Jackson Cullison, Elaine C Siegfried
New-onset psoriasis in patients receiving tumor necrosis factor inhibitors is well recognized in children and adults. We describe three children who underwent cardiac transplantation and developed an analogous form of paradoxic eczema occurring 2-48 months after starting systemic tacrolimus, a drug widely used topically to treat eczema. Anecdotal reports and our experience suggest that tacrolimus taper with alternative systemic antirejection immunosuppressant may lead to skin clearance. Pending additional insight, treatment should include optimizing skin barrier function, minimizing microbial and allergic triggers, and coordinating care to choose the best-tolerated systemic immunosuppressant regimen at the lowest effective dose...
January 2018: Pediatric Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"